Questcor Pharmaceuticals — J.P. Morgan Healthcare Conference 2014
44 slides from Questcor Pharmaceuticals's conference presentation, Jan 13, 2014

Slide 1: J.P. Morgan Healthcare Conference
Exhibit 99.1 NASDAQ: QCOR J.P. Morgan Healthcare Conference January 16, 2014

Slide 2: Safe Harbor Statement
Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performanc

Slide 3: Questcor
Questcor A biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders 3

Slide 4: Investment Highlights
Investment Highlights Flagship product H.P. Acthar Gel has a unique therapeutic role and sustainable competitive advantages Acthar is approved for 19 indications, many in markets with sizable unmet need Market penetration remains modest; sales have increased rapidly Increasing investment in R&D to g

Slide 5: 3-Year Net Sales
3-Year Net Sales Quarterly Net Sales ($M) $236.3 $184.6 $160.5 $112.5 $140.3 $135.1 $75.5 $46.0 $96.0 $29.3 $59.8 $31.3 $36.8 Q3 '10 Q4 '10 Q1 '11 Q2 '11 Q3 '11 Q4 '11 Q1 '12 Q2 '12 Q3 '12 Q4 '12 Q1 '13 Q2 '13 Q3 '13 5

Slide 6: Acthar Business Diversification Continues
Acthar Business Diversification Continues Net Sales Acthar Estimated % Net Sales by ($M) Therapeutic Area (Q3 2013) $717 Other Infantile Spasms ~2% 7%-12% $509 Nephrology 30%-35% Rheumatology 20%-25% $218 $115 $88 MS 2009 2010 2011 2012 TTM 2013 25%-30% TTM 2013: Trailing twelve months through Septe

Slide 7: Expanding Acthar Sales Across Therapeutic Areas
Expanding Acthar Sales Across Therapeutic Areas Acthar Net Sales ($M) $717 Other Rheumology $509 Nephrology Multiple Sclerosis Infantile Spasms $218 $115 $88 2009 2010 2011 2012 TTM 2013 *Numbers on the bar graph represent actual Acthar net sales. The underlying allocation of Acthar net sales is bas

Slide 8: Net Income Growth
Net Income Growth GAAP Net Income ($M) Non-GAAP Net Income ($M) $299 $265 CAGR $210 CAGR $198 79% 77% $80 $84 $35 $29 $39 $27 2009 2010 2011 2012 TTM 2013 2009 2010 2011 2012 TTM 2013 TTM 2013: Trailing twelve months through September 30, 2013; See reconciliation table in Appendix 8

Slide 9: Earnings Growth
Earnings Growth GAAP Diluted EPS Non-GAAP Diluted EPS $4.89 $4.34 CAGR 83% $3.33 CAGR $3.14 81% $1.21 $1.27 $0.40 $0.54 $0.44 $0.60 2009 2010 2011 2012 TTM 2013 2009 2010 2011 2012 TTM 2013 TTM 2013: Trailing twelve months through September 30, 2013; See reconciliation table in Appendix 9

Slide 10: Q3-2013 Financial Results
Q3-2013 Financial Results Q3 – 2013 Q3 – 2012 Change Net Sales ($M) $236.3 $140.3 68% Fully Diluted, GAAP EPS $1.52 $0.91 67% Fully Diluted, Non-GAAP EPS $1.68 $0.97 73% Cash and Short Term $281.1* $111.9 Investments ($M) Cash Flow from Operations ($M) $108.9 $51.2 Diluted Shares Outstanding 62.1 61

Slide 11: Recent Updates and Trends
Recent Updates and Trends • $0.30 Dividend declared Q413 Total Paid Acthar Rxs – Record date: 1/17/14 3,000 – Distribution date: 1/24/14 • 960K shares repurchased in Q413 2,500 • $320M in Cash and ST Investments* 2,000 • Board level Science and Strategic Advisory Committees formed 1,500 – To assist

Slide 12: Acthar Overview
Acthar Overview Flagship Product: • 19 approved indications Key Therapeutic Areas: • Nephrotic Syndrome, Multiple Sclerosis Relapse, Infantile Spasms, Rheumatology Indications, Symptomatic Sarcoidosis • Significant areas of unmet need; large growth potential Strategy: • Expand awareness, appropriate

Slide 13: Nephrotic Syndrome
Nephrotic Syndrome iMN, FSGS, IgA, LN, • Characterized by excessive spilling of MPGN, MCD Sub-Nephrotic Nephrotic protein from the kidneys into the urine ~90,000 Population (nephrotic-range proteinuria) ~35K • Caused by a number of underlying types of kidney disease (eg, iMN, FSGS, IgA nephropathy,

Slide 14: Multiple Sclerosis (MS) Relapse
Multiple Sclerosis (MS) Relapse • MS is a neurodegenerative disease Adequately Addressable occurring in about 400,000 patients Treated Relapses Patient in the US ~70K Population ~30K • Estimated >100,000 relapses/year • Relapses range from mild to severe and can cause a range of symptoms – Loss of s

Slide 15: Infantile Spasms (IS)
Infantile Spasms (IS) • Devastating, ultra-rare form of childhood epilepsy • Can cause permanent developmental disabilities, increased mortality • Acthar is often considered the “gold standard” and is currently used to treat ~50% of IS patients Acthar Penetration ~780 Pts ~1,500 Patients (US) 15

Slide 16: Rheumatology Acthar's Largest Market Opportunity
Rheumatology Acthar’s Largest Market Opportunity • Rheumatology-related indications Approximately 250,000 combined patients on the Acthar label* (US) are believed to be in need of additional – Dermatomyositis/Polymyositis treatment options – Systemic lupus erythematosus jRA – Rheumatoid arthritis -

Slide 17: Initiating a Pilot Commercialization Effort in Pulmonology
Initiating a Pilot Commercialization Effort in Pulmonology • Acthar is approved for the Asymptomatic Potential or Adequately Acthar Patients treatment of respiratory Treated ~20K manifestations of symptomatic ~130K sarcoidosis – A systemic inflammatory disease where cell nodules or granulomas can ma

Slide 18: Large Addressable Markets with Growth Potential (U.S. Only)
Large Addressable Markets with Growth Potential (U.S. Only) Potential Acthar % Acthar Penetration Indication Patient Population (estimated) Note: Amounts and percentages based on internal company estimates. 18

Slide 19: Large Addressable Markets with Growth Potential (U.S. Only)
Large Addressable Markets with Growth Potential (U.S. Only) Potential Acthar % Acthar Penetration Indication Patient Population (estimated) NEUROLOGY Infantile Spasms 1,500 52% Note: Amounts and percentages based on internal company estimates. 19

Slide 20: Large Addressable Markets with Growth Potential (U.S. Only)
Large Addressable Markets with Growth Potential (U.S. Only) Potential Acthar % Acthar Penetration Indication Patient Population (estimated) NEUROLOGY Infantile Spasms 1,500 52% Multiple Sclerosis Flares 30,000 18% Note: Amounts and percentages based on internal company estimates. 20

Slide 21: Large Addressable Markets with Growth Potential (U.S. Only)
Large Addressable Markets with Growth Potential (U.S. Only) Potential Acthar % Acthar Penetration Indication Patient Population (estimated) NEUROLOGY Infantile Spasms 1,500 52% Multiple Sclerosis Flares 30,000 18% NEPHROLOGY Nephrotic Syndrome 35,000 9% Note: Amounts and percentages based on interna

Slide 22: Large Addressable Markets with Growth Potential (U.S. Only)
Large Addressable Markets with Growth Potential (U.S. Only) Potential Acthar % Acthar Penetration Indication Patient Population (estimated) NEUROLOGY Infantile Spasms 1,500 52% Multiple Sclerosis Flares 30,000 18% NEPHROLOGY Nephrotic Syndrome 35,000 9% RHEUMATOLOGY PM/DM 20,000 2% Rheumatoid Arthri

Slide 23: Large Addressable Markets with Growth Potential (U.S. Only)
Large Addressable Markets with Growth Potential (U.S. Only) Potential Acthar % Acthar Penetration Indication Patient Population (estimated) NEUROLOGY Infantile Spasms 1,500 52% Multiple Sclerosis Flares 30,000 18% NEPHROLOGY Nephrotic Syndrome 35,000 9% RHEUMATOLOGY PM/DM 20,000 2% Rheumatoid Arthri

Slide 24: Synacthen (tetracosactide) Overview
Synacthen (tetracosactide) Overview • Acquired license to develop and commercialize Synacthen and Synacthen Depot in U.S. • Rights to develop and commercialize in over three dozen countries* – Opportunity to reinvigorate Synacthen and provides platform for potential international growth • Expands pr

Slide 25: Advancing Our Understanding of Acthar and Melanocortin Peptides
Advancing Our Understanding of Acthar and Melanocortin Peptides • One of 9 families of hormones produced by the pituitary, the “master gland” • Believed to modulate the immune system and associated inflammatory process through binding to 5 melanocortin receptors – MC1R, MC2R, MC3R, MC4R, and MC5R –

Slide 26: Acthar Mechanism of Action
Acthar Mechanism of Action • Clinical observations – Acthar has been shown to have increased efficacy vs. corticosteroids in infantile spasms – Acthar has been successfully used to induce remission of proteinuria in nephrotic syndrome without uremia of the idopathic type 1 (e.g., iMN, FSGS, IgA neph

Slide 27: Implications of Acthar and Other Melanocortins
Implications of Acthar and Other Melanocortins (Synacthen and new MCs) • We now believe Acthar and other melanocortin peptides impact – Immune system – Inflammatory process – Some cell function – Homeostasis • Dozens of moderate-to-severe medical conditions may benefit from Acthar or other melanocor

Slide 28: Significantly Increasing Investment in R&D
Significantly Increasing Investment in R&D • Have funded or have approved R&D Investment ($M) funding for studies covering both on label and potential $52 new indications – Company sponsored pre-clinical and clinical studies – Independent physician sponsored $34 studies • Investigating potential bio

Slide 29: Expanding the Body of Evidence for On-Label and New Indications/Targets
Expanding the Body of Evidence for On-Label and New Indications/Targets Pre-Clinical Phase 1 Phase 2 Phase 3 Phase 4 IDIOPATHIC MEMBRANOUS NEPHROPATHY SYSTEMIC LUPUS ERYTHEMATOSUS DIABETIC NEPHROPATHY AMYOTROPHIC LATERAL SCLEROSIS ACUTE RESPIRATORY DISTRESS SYNDROME 29

Slide 30: ALS Phase 2 Open-Label Safety Study for Acthar
ALS Phase 2 Open-Label Safety Study for Acthar • Goals – Assess short-term safety and tolerability of Acthar in ALS – Inform dosage selection for future studies • Study Design – Enroll up to 40 patients at multiple sites in U.S. – 8-week treatment, plus optional 28-week open label extension – Patien

Slide 31: ARDS Phase 2 Safety and Efficacy Study for Acthar
ARDS Phase 2 Safety and Efficacy Study for Acthar • Goals – Determine if Acthar increases number of ventilator-free days during 28-day treatment period – Assess if Acthar reduces mortality, organ failure, length of hospital or ICU stay – Inform dosage selection for future studies • Study Design – 4-

Slide 32: Strong Platform for Growth
Strong Platform for Growth • Increasing penetration of current Acthar markets and expanding sales into new, approved indications – NS and MS market penetration remains modest – Rheumatology is a new Acthar market in very early development; growing rapidly – Pilot selling effort in pulmonology for sy

Slide 33: Growing Cash Flow
Growing Cash Flow Operating Cash Flow ($M) $316 $219 $86 $40 $37 2009 2010 2011 2012 2013TTM TTM 2013: Trailing twelve months through September 30, 2013 33

Slide 34: Committed to Creating Long Term Value for Shareholders
Committed to Creating Long Term Value for Shareholders • Continued stewardship of Acthar and Synacthen • Demonstrated ability to execute • Long term investment in R&D -- doubled R&D spending in 2012 and 2013 (projected) • Highly selective, strategic diversification • Have returned $465 million to sh

Slide 35: NASDAQ: QCOR
NASDAQ: QCOR January 2014 (WW QUESTCOR’

Slide 36: Reconciliation of Non-GAAP Adjusted Financial Disclosure
Reconciliation of Non-GAAP Adjusted Financial Disclosure Three Months Nine Months Ended Ended Notes to Reconciliation of Non-GAAP Adjusted Financial September 30, September 30, 2013 2012 2013 2012 Disclosure $104,36 $233,32 $143,94 Adjusted net income $59,427 8 8 3 Net income per share – basic and d

Slide 37: Reconciliation of Non-GAAP Adjusted Financial Disclosure
Reconciliation of Non-GAAP Adjusted Financial Disclosure 2009 2010 2011 2012 TTM 2013 Adjusted Net Income $29,242 $38,988 $83,956 $209,644 $299,033 Stock-based Compensation (2,310) (2,649) (5,128) (10,502) (17,396) Depreciation & Amortization Expense (303) (352) (731) (811) (6,428) Other non-cash ex

Slide 38: Acthar Label: Rheumatic Disorders and Collagen Diseases
Strong Platform for Growth • 1.3 Rheumatic Disorders: – As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintena

Slide 39: How Does Acthar Work?
How Does Acthar Work? • Treats autoimmune/inflammatory process associated with the pathophysiology 1-4 • By binding to melanocortin receptors, may modulate the immune system and associated inflammatory process 1,5-9 • Triggers the production of cortisol and other adrenal compounds through binding to

Slide 40: Melanocortin Peptides May Activate Up to Five Known Melanocortin Receptors
Melanocortin Peptides May Activate Up to Five Known Melanocortin Receptors Acthar MC2R MC1R MC3R MC4R MC5R Adrenal cortical cells Immune cells, CNS cells, kidney cells, muscle cells, Corticosteroids many other cells Steroid-independent anti-inflammatory/immunomodulatory effects Steroid-dependent ant

Slide 41: MCR Tissue/Cell Expression Potential biologic activity
MCR Tissue/Cell Expression Potential biologic activity Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, • Immunomodulation (including modulation of antigen presentation; immune cell adhesion and Tubular, Vascular) trafficking; dampen autoimmunity; NF- Macrophages, Monocytes, Neutrophil

Slide 42: New Paid Acthar Prescriptions by Therapeutic Area
New Paid Acthar Prescriptions by Therapeutic Area* Paid Rx Comparison Q3 – 2013 Q3 – 2012 Q2 – 2013 NS 370 - 380 7% 7% MS 1,370 - 1,400 4% 8% IS 225 - 230 33% 7% Rheumatology 450 - 460 N/M 43% Total 2,450 - 2,500** 30% 10% * Includes prescriptions covered by commercial carriers, Medicare, Medicaid a

Slide 43: Biosimilar Pathways Highly Challenging
Biosimilar Pathways Highly Challenging • Complex formulation and pharmacology, with multiple receptor binding properties – Possibly multiple active peptides – Slow release gel formulation – Complex and not well characterized (research is ongoing) • Formulation and manufacturing trade secrets inheren

Slide 44: NASDAQ: QCOR
NASDAQ: QCOR January 2014 (WW QUESTCOR’
Source: SEC EDGAR · 8-K filed Jan 13, 2014
More decks from Questcor Pharmaceuticals Inc
FY2013 Earnings Presentation19 slides · Mar 3, 2014
Oppenheimer Healthcare Conference 201337 slides · Dec 11, 2013
Q3 2013 Earnings Presentation17 slides · Nov 4, 2013
Q2 2013 Earnings Presentation14 slides · Aug 6, 2013
Investor Presentation (August 2013)29 slides · Aug 6, 2013
Bank of America Merrill Lynch Healthcare Conference 201325 slides · May 14, 2013